Proteomic avenues for clinical diagnosis: where are they leading?
New technologies make possible increasingly comprehensive and quantitative assessment of the suite of proteins and peptides and all their modified forms (the proteomes) present in biological samples. These proteomic technologies should facilitate the discovery of new and more efficient protein and peptide biomarkers. However, the discovery rate of new, clinically useful diagnostic markers appears not to have been influenced by the technological advances over the last 5 years. In reality, the opposite, that is, a decreasing trend in the number of new protein biomarkers approved for clinical use, has been observed. The possible reasons for this paradox and the remedies that are going to make the next generation of proteomic biomarker projects more likely to contribute to medical diagnostics are discussed in this editorial.